BOWIE, MD – November 14, 2014 – Inovalon, Inc., a leading technology company providing advanced cloud-based analytics and data-driven intervention platforms to the healthcare industry, today announced quality performance measurement research on preventative mammography screening to be presented at the American Public Health Association’s (APHA) 142nd Annual Meeting & Expo in New Orleans, Louisiana, on Sunday, November 16th at 2:30 pm in the session of Policy & Finance and Health Service Research.
The study, “Utilization of Breast Cancer Screening among Medicare Advantage Enrollees,” assesses the association between the utilization of Breast Cancer Screening (BCS) and specific patient characteristics to identify those members of Medicare Advantage (MA) plans who are less likely to undergo important preventive screening. Early detection has been shown to lead to better and more effective treatment options and reduce mortality. The study found that the utilization of BCS increased from age 52 to 67, but then declines from age 67 to 74. This large population-based analysis identified specific subgroups of women who are less likely to utilize BCS, including women at both the lower and upper end of the age range included in the measure, disabled women, institutionalized patients, and women without diagnosed chronic conditions. According to the study, strategic efforts initiated by health plans focused on members identified through the research as being less likely to have a mammogram can effectively and efficiently increase BCS detection. These targeted interventions can positively impact population health for women, while improving health plan performance on this quality metric.
“Inovalon is harnessing the power of large longitudinal data using sophisticated statistical analytics to better understand differential performance on quality measures at the member level,” said Christie Teigland, PhD, Director of Statistical Research at Inovalon. “The goal of this research is to identify characteristics of patients at greatest risk for not undergoing this important preventive screening to help guide interventions and policies aimed at improving long term health outcomes for women.”
The study was supported by data from Inovalon’s Medical Outcomes Research for Effectiveness and Economics Registry (MORE2 Registry®). Inovalon’s Statistical Research Team co-authors include: Ping Chen, MD MS; Barton T. Jones, MS; Sandhya Mehta, PhD; Alexis Parente, PhD; Zulkarnain Pulungan, PhD; Jeanette Hunsberger, BS and Christie Teigland, PhD.
About Inovalon, Inc.
Inovalon is a leading technology company that combines advanced cloud-based data analytics and data-driven intervention platforms to achieve meaningful impact in clinical and quality outcomes, utilization, and financial performance across the healthcare landscape. Inovalon’s unique achievement of value is delivered through the effective progression of Turning Data into Insight, and Insight into Action®. Large proprietary datasets, advanced integration technologies, sophisticated predictive analytics, and deep subject matter expertise deliver a seamless, end-to-end platform of technology and nationwide operations that bring the benefits of big data and large-scale analytics to the point of care. Driven by data, Inovalon uniquely identifies gaps in care, quality, data integrity, and financial performance – while also bringing to bear the unique capabilities to resolve them. Supporting hundreds of healthcare organizations in 98% of U.S. counties and Puerto Rico, Inovalon’s analytical and data-driven intervention platforms are informed by data pertaining to more than 744,000 physicians, 244,000 clinical facilities, and more than 118 million Americans providing a powerful solution suite that drives high-value impact, improving quality and economics for health plans, ACOs, hospitals, physicians, patients, and researchers. For more information visit www.inovalon.com.
4321 Collington Road
Bowie, Maryland 20716
on behalf of Inovalon, Inc.